The work focuses on the biological events that occur when antigen-presenting cells communicate with T lymphocytes. This interaction is essential for adaptive immunity, particularly against viruses that replicate inside host cells, where antibodies may have limited access. Antibodies can block viral particles before they enter cells or help mark extracellular pathogens for destruction, but they generally cannot directly remove virus from an infected cell. That task depends heavily on cytotoxic T lymphocytes, often called killer T cells, which recognize fragments of viral proteins displayed on the surface of infected cells and destroy those cells before the infection can spread further.

Although many vaccines induce effective antibody responses, generating equally robust and durable T-cell immunity remains more difficult. The challenge is especially important for viruses that establish intracellular reservoirs, replicate rapidly, or alter the surface of infected cells in ways that complicate immune recognition. Protective T-cell responses require more than the simple presentation of a viral fragment. T cells must receive a coordinated set of molecular signals that determines whether they become activated, how extensively they multiply, which tissues they enter and how long they persist. The quality and timing of those signals can influence whether the resulting response is protective, weak, short-lived or excessively inflammatory.

Liu’s laboratory will examine how antigen-presenting cells control this process. These cells, which include dendritic cells, macrophages and other specialized immune populations, capture material from pathogens or infected tissues and process it into peptide fragments. The fragments are loaded onto major histocompatibility complex molecules and displayed to T cells. Presentation through MHC class I molecules is particularly important for activating CD8-positive T cells, the population that can develop into virus-killing cytotoxic lymphocytes. Antigen-presenting cells also provide co-stimulatory signals and release cytokines that help determine the functional characteristics of the T-cell response.

A key question is how antigen-presenting cells translate information about a pathogen into distinct instructions for T cells. The same viral antigen may produce very different immune outcomes depending on the type of presenting cell, the inflammatory environment, the location of the encounter and the duration of antigen exposure. Dendritic cells, for example, can acquire viral material without being infected themselves and present it to CD8-positive T cells through a pathway known as cross-presentation. This mechanism allows the immune system to initiate cellular immunity against pathogens that may not directly infect the dendritic cell. Understanding how cross-presentation is regulated could reveal ways to improve vaccines against viruses that are difficult to control with antibodies alone.

The activation of a naïve T cell is a highly structured process involving the formation of an immune synapse between the T cell and the antigen-presenting cell. The T-cell receptor scans peptide–MHC complexes, while additional receptor–ligand interactions provide co-stimulation and stabilize the cellular contact. Intracellular signaling networks then reorganize the T cell’s metabolism, gene expression and cytoskeleton. These changes determine whether the cell enters rapid proliferation, differentiates into an effector cell that can kill infected targets, or forms a memory population capable of responding during a later exposure. Liu’s project seeks to clarify how the presenting cell helps coordinate these signals rather than treating antigen recognition as an isolated event.

The research could also address why some vaccine formulations induce strong antibody production but relatively modest cellular immunity. Vaccine components are sensed by innate immune receptors, and those early signals shape the behavior of antigen-presenting cells before T-cell activation begins. If the presenting cells do not mature appropriately, migrate efficiently to lymphoid tissues or express the right combination of co-stimulatory molecules and cytokines, T-cell priming may be incomplete. Conversely, overly intense stimulation can produce inflammation without generating a durable, well-organized memory response. Defining the molecular features associated with effective T-cell priming could help researchers design immunization strategies that more precisely direct the immune system.

The potential implications extend beyond preventive vaccines. A better understanding of antigen-presenting cell biology could support the development of therapeutic vaccines for chronic viral infections and improve approaches that use T cells to target infected or abnormal cells. Researchers may ultimately be able to manipulate antigen presentation, co-stimulation or cytokine signaling to strengthen antiviral immunity while limiting harmful immunopathology. Such strategies could be valuable when the immune response itself contributes to tissue damage, a recurring concern in severe viral disease. However, Liu’s award is focused on fundamental biology, and any clinical applications will depend on findings that emerge from the laboratory studies.

The NIAID New Innovators Award was established to support creative research by early-stage investigators whose ideas challenge established approaches or address broad biomedical problems. For Liu, the central goal is to identify the rules governing communication between antigen-presenting cells and T cells, then use that knowledge to influence the immune response in a controlled way. “We want to better understand how the immune cells involved in the T cell activation work, then use those discoveries to manipulate it in ways that help treat infectious diseases,” she said. By defining how cellular interactions shape antiviral T-cell immunity, the project may provide a framework for developing vaccines and immunotherapies that do more than prevent viral entry: they could help the immune system locate, recognize and eliminate infected cells.

The project will be conducted at Scripps Research, where Liu is an assistant professor. Its stated purpose is to advance basic understanding rather than report an immediate therapeutic result, and the research is not yet evidence that a particular vaccine or treatment will follow. Still, the questions it addresses are central to the future of viral disease control. As emerging and persistent viruses continue to expose the limitations of antibody-only protection, deciphering how antigen-presenting cells initiate and shape killer T-cell responses could become a critical step toward more complete and adaptable antiviral immunity.

Subject of Research: Antigen-presenting cells, T-cell activation, cytotoxic T lymphocytes, antiviral immunity and next-generation immunotherapies.

Web References: Scripps Research faculty profile: https://www.scripps.edu/faculty/tliu/ ; NIH RePORTER project details: https://reporter.nih.gov/search/Tf6_eiF25UellUnlp55ryw/project-details/11436857

References: NIAID DP2 New Innovators Award, grant number 1DP2AI201038-01; Scripps Research press information provided in the source content.

Image Credits: Scripps Research; image subject Tiantian Liu.

Keywords: Viral immunology, T lymphocytes, cytotoxic T cells, antigen-presenting cells, cross-presentation, MHC class I, vaccine research, antiviral immunity, immunotherapy, Scripps Research, NIAID DP2 award.

Lymph nodes, small pea-sized anatomical structures strategically dispersed along lymphatic vessels, function as vital immunological hubs. These nodes scrutinize lymph fluid, a clear bodily fluid transporting immune cells and antigens, to detect and respond swiftly to potential pathogenic threats. Their internal structure displays a remarkable degree of compartmentalization, with distinct microenvironments housing specific immune cell populations such as cytotoxic T lymphocytes and dendritic cells. Yet, the molecular cues defining this intricate spatial patterning have remained elusive until now.

The research team focused on elucidating the mechanisms by which certain immune cells, particularly cytotoxic T lymphocytes, localize centrally within the lymph node. These killer T cells are essential for targeted destruction of infected or malignant cells. Their strategic colocalization with type 1 dendritic cells — specialized sentinel cells that present pathogen-derived danger signals — optimizes immune response activation. Despite the recognized importance of this cellular arrangement, the molecular underpinnings that choreograph this positioning remained poorly understood.

Long-standing interest in the interplay between fibroblasts — structural stromal cells within lymphoid organs — and immune cells led the researchers to examine fibroblast heterogeneity. Their findings reveal a distinct fibroblast subset, characterized by expression of the adhesion molecule MAdCAM1, residing in the lymph node’s central regions. These fibroblasts produce high levels of the chemokine Ccl19, a potent attractant that guides cytotoxic T lymphocytes into proximity with type 1 dendritic cells, establishing optimal cell niches essential for immune activation and memory formation.

Crucially, the study disentangles the molecular signaling axis maintaining this fibroblast identity and function. A Notch2 receptor-RBPj transcriptional pathway within these fibroblasts governs their specialization and continuous Ccl19 production. Initiation of this signaling cascade is orchestrated by Jagged-1, a ligand predominantly expressed on type 1 dendritic cells. This crosstalk epitomizes a sophisticated reciprocal cellular regulation wherein dendritic cells instruct fibroblast specialization, thereby sculpting the lymph node microenvironment favorable for effective T cell responses.

Experimental models lacking Notch2 specifically in fibroblasts exhibit disrupted lymph node architecture, resulting in impaired cytotoxic T lymphocyte memory development. This deficiency compromises the immune system’s ability to mount rapid and robust secondary responses upon re-exposure to pathogens or tumor cells. These insights implicate Notch2-mediated fibroblast programming as an indispensable component of immune memory establishment and durable protection.

Beyond the architecture of lymph nodes, the researchers extended their analysis to other lymphoid tissues, including the spleen and intestinal Peyer’s patches. Remarkably, the Notch2-dependent regulation of Ccl19-producing fibroblasts appears conserved across these organs, underscoring a fundamental, evolutionarily conserved strategy to maintain immune cell compartmentalization. Parallel characterization of human lymph nodes revealed a similar fibroblast subset and Notch2 signaling dynamics, suggesting translational relevance to human immunology.

This research represents a paradigm shift in immunobiology, illustrating how structural fibroblasts are not mere passive scaffolds but active regulators dictating immune cell behavior and positioning. By elucidating how fibroblast specialization is instructed and maintained, the study opens new avenues to manipulate immune niches, potentially enhancing immunotherapies or vaccine efficacy by optimizing T cell priming and memory formation.

Further exploration may reveal whether dysregulation of this fibroblast-immune cell dialogue contributes to immune evasion by tumors or persistent infections. Understanding these mechanisms at a molecular level holds promise for innovative therapeutics aimed at restoring or enhancing immune system organization, particularly in immunocompromised individuals or those with chronic inflammatory conditions.

This work is emblematic of the growing recognition that the immune system operates as an intricately coordinated multicellular network, where stromal and immune cells engage in continuous, dynamic conversations. Addressing the spatial and molecular frameworks of these interactions will be key to unraveling complex immune dysfunctions and tailoring precise, cell-targeted interventions.

The University of Lausanne’s study, published in the prestigious journal Immunity in April 2026, embodies a substantial leap forward in conceiving immune system functionality not merely as a collection of mobile immune effectors but as a precisely organized cellular ecosystem dependent on stromal-immune cell crosstalk. Such foundational knowledge paves the way for next-generation immunological research and therapeutic innovation.

The findings underscore the necessity of maintaining the Notch2 signaling axis lifelong to preserve lymph node architecture and immune competence, highlighting how continuous cell signaling regulates not only development but also ongoing immune readiness throughout an organism’s lifespan.

As immunologists delve deeper into stromal roles within lymphoid organs, targeting fibroblast subsets or manipulating their Notch2-dependent pathways may emerge as viable strategies for refining immune modulating approaches. This could revolutionize treatments for infectious diseases, cancer, and autoimmune disorders by tailoring the microenvironmental context to favor protective immune responses.

Ultimately, this discovery not only enriches our fundamental understanding of immune orchestration but also revitalizes consideration of lymph node stromal elements as active participants and potential therapeutic targets in the ever-evolving battle against pathogenic threats and cancer.

Subject of Research: Immune system spatial organization and fibroblast-immune cell interactions in lymph nodes

Article Title: Homeostatic mature dendritic cells instruct fibroblast specialization via Notch2 signaling to establish T cell niches

News Publication Date: 23-Apr-2026

Web References:
DOI: 10.1016/j.immuni.2026.03.023

Keywords: lymph nodes, immune system organization, fibroblast specialization, Notch2 signaling, cytotoxic T lymphocytes, dendritic cells, Ccl19 chemokine, immune memory, stromal cells, immune microenvironment